Event Date/Time: Aug 13, 2013 End Date/Time: Aug 15, 2013
Early Registration Date: Jul 19, 2013
Abstract Submission Date: Jul 19, 2013
Report as Spam



Recent advances in cancer immunotherapy have turned researcher's attentions to new therapeutic strategies focused on improved specificity, control of key checkpoints in immune response, the identification of new biomarkers and novel ways of combining therapies for maximum effect. The two-conference Immunotherapies Congress offers an exciting opportunity to learn how these strategies are being translated into the next generation of cancer immunotherapeutic drug products.   The first meeting, Emerging Cancer Immunotherapies and Vaccines (August 13-14), will examine new targets and strategies in this space, and explore how the lessons learned from early cancer vaccines are driving development of longer-lasting and more potent immune responses. A second conference, Immunomodulatory Therapeutic Antibodies for Cancer (August 14-15) showcases the exciting wave of checkpoint blockades such as anti-PD-1 and anti-CTLA-4 now in clinical development -- and explores considerations of trial design, drug safety and biomarker discovery that will influence their application in patients.


40 Dalton St
United States

Conference Speakers


  • Adam J. Adler, Ph.D., Associate Professor of Immunology, University of Connecticut
  • Michel Sadelain, M.D., Ph.D., Director, Center for Cell Engineering & Gene Transfer and Gene Expression Laboratory, Memorial Sloan-Kettering Cancer Center
  • Daniel J. Powell, Jr., M.D., Assistant Professor, Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania
  • Rakesh K. Jain, Ph.D., Andrew Werk Cook Professor of Tumor Biology, Harvard Medical School; Director, E.L. Steele Laboratory of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital
  • Susan R. Slovin, M.D., Ph.D., Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan–Kettering Cancer Center
  • Zachary Cooper, Ph.D., Postdoctoral Research Associate, Surgical Oncology, Massachusetts General Hospital
  • John Doukas, Ph.D., Senior Director, Preclinical Safety and Efficacy, Vical, Inc.
  • K. Dane Wittrup, Ph.D., Dubbs Professor, Chemical Engineering and Biological Engineering, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
  • Robert Holt, Ph.D., Senior Scientist and Head of Sequencing, British Columbia Cancer Agency, Canada
  • Dafne Müller, Ph.D., Researcher, Institute of Cell Biology and Immunology, University of Stuttgart, Germany
  • Ana Carrizosa Anderson, Ph.D., Assistant Professor, Neurology, Harvard Medical School
  • Richard P. Junghans, M.D., Professor, Department of Medicine, Boston University School of Medicine; Roger Williams Medical Center
  • Anne Moon, Ph.D., Vice President, Product Development, Jennerex
  • David E. Avigan, M.D., Associate Professor, Medicine, Harvard Medical School; Director, Hematologic Malignancy/Bone Marrow Transplant Program, Beth Israel Deaconess Medical Center
  • James Trager, Ph.D., Vice President, Research, Dendreon
  • Kevin Heller, Global Lead Oncology; Search, Evaluation and Diligence, Bristol-Myers Squibb
  • Alain Delcayre, Ph.D., Vice President, R&D, BN Immunotherapeutics
  • Padmanee Sharma, M.D., Associate Professor, Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
  • Omid Hamid, M.D., Director, Melanoma Center, Angeles Clinic and Research Institute
  • Lauren Harshman, M.D., Assistant Professor, Dana-Farber Cancer Institute
  • Sattva S. Neelapu, M.D., Associate Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
  • Solomon Langermann, Ph.D., CSO, Amplimmune
  • Lawrence J. Thomas, Ph.D., DABT, CMAR, Senior Director, Preclinical Research and Development, Celldex Therapeutics, Inc. 
  • Catherine Hutchinson, Ph.D., Research Scientist, Philochem, Switzerland
  • Paul Moore, Ph.D., Vice President, Cell Biology & Immunology, Macrogenics
  • Timo van den Berg, Ph.D., Head, Blood Cell Research, Sanquin Blood Supply Foundation, The Netherlands
  • Lex Bakker, Ph.D., Chief Development Officer, Merus, The Netherlands
  • Harriet Kluger M.D., Associate Professor, Yale Cancer Center
  • Stephanie Andrews, Oncology Nurse Practitioner, Moffitt Cancer Center
  • Rakesh Dixit, Ph.D., DABT, Vice President, Research & Development, Global Head, Biologics Safety Assessment, Pathology & LAR, MedImmune (AstraZeneca Biologics)
  • Krzysztof Masternak, Ph.D., Head of Biology, Novimmune SA, Switzerland